Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.
|Number of pages||6|
|Publication status||Published - 2014 May|
Bibliographical noteFunding Information:
This work was funded by Korea Otsuka pharmaceuticals. The design, analysis, interpretation of the data and decision to publish was the sole responsibility of the authors and independent of the funders.
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine